Truscreen Group Limited announced the appointment of Dr. Beata Edling as Chief Executive Officer. Dr. Edling joined TruScreen in October 2020 as Medical Affairs and Market Access Lead and has developed an intimate knowledge of the TruScreen cervical cancer screening technology and business. She led the medical affairs and market access of TruScreen into new markets in Eastern Europe and the Balkan nations and inaugurated TruScreen's International Experts Group.

Dr. Edling has also worked closely with TruScreen's major distributors in China and in Vietnam. Dr. Edling holds a MD from the Medical University, Gdansk, Poland, and has completed part 1 of her Fellowship with Royal College of Surgeons, Australia. Dr. Edling completed her PhD at the University of New South Wales, Australia, has a MBA from Sydney's Australian Graduate School of Management, and is a graduate member of the Australian Institute of Company Directors.

Dr. Edling is an experienced executive who previously led large and small Medical Affairs Teams and commercialised numerous medical products with global pharmaceutical companies, Sanofi-Aventis, Shire, Eli Lily and Amgen for Australia and New Zealand. Dr. Edling was previously a Non-Executive Director of ASX listed Noxopharm Limited. Dr. Edling is multi-lingual and speaks several European languages.